The document is a financial analysis report by J.P. Morgan Cazenove on Roche, focusing on the market potential of Roche's PD-L1 in bladder cancer and other tumor types. It discusses the potential financial impact of upcoming data presentations at ASCO, including the combination with Avastin and other drugs. The report reiterates an 'Overweight' rating with a price target of SFr280, indicating a 9% potential upside. It includes detailed financial metrics and forecasts for Roche, as well as expected news flow for 2014.
documents/EFTA00309574.pdf
{}